Literature DB >> 2154612

Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.

G R Nemerow1, J J Mullen, P W Dickson, N R Cooper.   

Abstract

Epstein-Barr virus (EBV), an oncogenic herpesvirus of humans, displays selective tropism for B lymphocytes and epithelial cells. EBV tropism is thought to be determined in part by a unique host cell receptor termed CR2 (CD21). Although previous studies have demonstrated that CR2 mediates EBV binding to B cells, its role in initiating EBV infection and B-cell transformation is less certain. In the studies reported here, soluble recombinant CR2 was shown to cause substantial inhibition of EBV infection of B cells in vitro, indicating that CR2 binding initiates EBV infection. Soluble CR2 may represent a therapeutic agent for acute and chronic EBV infections in humans.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2154612      PMCID： PMC249254          DOI： 10.1128/JVI.64.3.1348-1352.1990

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  27 in total

1.  HIV infection is blocked in vitro by recombinant soluble CD4.

Authors:  R A Fisher; J M Bertonis; W Meier; V A Johnson; D S Costopoulos; T Liu; R Tizard; B D Walker; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

2.  Soluble CD4 molecules neutralize human immunodeficiency virus type 1.

Authors:  A Traunecker; W Lüke; K Karjalainen
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

3.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.

Authors:  R E Hussey; N E Richardson; M Kowalski; N R Brown; H C Chang; R F Siliciano; T Dorfman; B Walker; J Sodroski; E L Reinherz
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

4.  Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein.

Authors:  G R Nemerow; M F Siaw; N R Cooper
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

5.  Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis.

Authors:  J Tanner; J Weis; D Fearon; Y Whang; E Kieff
Journal:  Cell       Date:  1987-07-17       Impact factor: 41.582

6.  Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors:  Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

7.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes.

Authors:  M D Moore; N R Cooper; B F Tack; G R Nemerow
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

9.  Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector.

Authors:  G E Smith; G Ju; B L Ericson; J Moschera; H W Lahm; R Chizzonite; M D Summers
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  A soluble form of CD4 (T4) protein inhibits AIDS virus infection.

Authors:  K C Deen; J S McDougal; R Inacker; G Folena-Wasserman; J Arthos; J Rosenberg; P J Maddon; R Axel; R W Sweet
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962
View more
  19 in total

1.  Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1.

Authors:  H Jenson; K McIntosh; J Pitt; S Husak; M Tan; Y Bryson; K Easley; W Shearer
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

Review 2.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

3.  Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.

Authors:  M D Moore; M J Cannon; A Sewall; M Finlayson; M Okimoto; G R Nemerow
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

4.  Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.

Authors:  Kendra A Young; Andrew P Herbert; Paul N Barlow; V Michael Holers; Jonathan P Hannan
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

5.  Origin and properties of soluble CD21 (CR2) in human blood.

Authors:  N R Ling; D L Hardie; G D Johnson; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

6.  Pitfalls in the measurement of soluble forms of cell surface receptors.

Authors:  N R Ling
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

7.  Identification of key residues in subgroup A avian leukosis virus envelope determining receptor binding affinity and infectivity of cells expressing chicken or quail Tva receptor.

Authors:  S L Holmen; D C Melder; M J Federspiel
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 8.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

9.  Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.

Authors:  Clemens Busse; Regina Feederle; Martina Schnölzer; Uta Behrends; Josef Mautner; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 10.  Epstein-Barr virus infection and associated diseases in children. II. Diagnostic and therapeutic strategies.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.